Clinical Report: How Are CGT Companies Rethinking Pricing and Reimbursement?

Overview

The discussion highlights the need for innovative pricing and reimbursement models for cell and gene therapies (CGT) that reflect their long-term value.

Background

As cell and gene therapies advance, traditional reimbursement models face challenges due to high upfront costs. The potential for these therapies to deliver long-term, curative benefits necessitates a reevaluation of how their value is measured.

Data Highlights

No numerical or trial data provided in the source material.

Key Findings

• Industry leaders advocate for outcomes-based agreements and staged payments.
• Value assessment should consider clinical outcomes and reduced hospitalizations.
• Effective communication with payers is essential for developing new reimbursement models.
• Long-term impact of therapies must be reflected in pricing strategies.
• Collaboration among stakeholders is necessary to navigate the evolving landscape of CGT reimbursement.

Clinical Implications

Healthcare providers should be aware of the shifting landscape in CGT pricing and reimbursement.

Conclusion

The ongoing dialogue among industry leaders is critical for developing reimbursement models.

Related Resources & Content

1. the medicine maker, The Medicine Maker, 2026 -- Roving Reporter Asks: Where Do You See the Most Progress in CGT Manufacturing and Scalability?
2. the medicine maker, The Medicine Maker, 2026 -- Roving Reporter Asks: What Are Recent Breakthroughs Telling Us About the CGT Field’s Maturity?
3. the medicine maker, The Medicine Maker, 2026 -- Roving Reporter Asks: What Was the Biggest Development in CGT of 2025?
4. Ophthalmology Management, Ophthalmology Management, 2012 -- Payer Contracting: What are Acceptable Rates?
5. CGT (Cell and Gene Therapy Access) Model | CMS, CMS, 2025-2026 -- CGT (Cell and Gene Therapy Access) Model
6. Clinical Review - Exagamglogene Autotemcel (Casgevy) - NCBI Bookshelf, NCBI Bookshelf -- Clinical Review - Exagamglogene Autotemcel (Casgevy)
7. Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results - PMC, PMC -- Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A
8. CGT (Cell and Gene Therapy Access) Model | CMS
9. Clinical Review - Exagamglogene Autotemcel (Casgevy) - NCBI Bookshelf
10. Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results - PMC